NFKB1 and colorectal carcinoma: PDX models have also been used to identify NF-κB, EGFR, and 12 other markers of cetuximab sensitivity and resistance, and to elucidate the combined inhibition of NF-κB and BET proteins as a potential combination therapy for CRC [74,75].